Patents by Inventor Shuyong ZHAO

Shuyong ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20240034743
    Abstract: Provided are a class of compounds, represented by formula (I??), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds of the present invention to treat cell proliferative diseases, such as cancers.
    Type: Application
    Filed: April 13, 2021
    Publication date: February 1, 2024
    Inventors: Shansong ZHENG, Wei DENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
  • NOVEL AMINOPYRIMIDINE EGFR INHIBITOR
    Publication number: 20230219986
    Abstract: The present invention provides a novel aminopyrimidine compound as a fourth-generation EGFR (T790M/C797S mutation) selective inhibitor, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compound, and a method for treating a cell proliferative disease, such as a cancer, by using the compound of the present invention.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 13, 2023
    Applicants: QILU PHARMACEUTICAL CO., LTD., QILU PHARMACEUTICAL CO., LTD.
    Inventors: Wei DENG, Shansong ZHENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
  • TRICYCLIC COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20230192734
    Abstract: Provided are a class of compounds, represented by formula (I??), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds of the present invention to treat cell proliferative diseases, such as cancers.
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Inventors: Shansong ZHENG, Wei DENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
  • ANTIBODY AGAINST CLAUDIN 18A2 AND USE THEREOF
    Publication number: 20220411492
    Abstract: Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.
    Type: Application
    Filed: May 15, 2020
    Publication date: December 29, 2022
    Applicant: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Yingying YANG, Gao LI, Yaning WANG, Zhenming AN, Shuyong ZHAO, Yuxue LIU, Shicong LIU, Meijuan ZHANG, Jinjin JIANG